Naratriptan

Naratriptan is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches.

Naratriptan

Naratriptan; 121679-13-8; Colatan; N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide; Naratriptanum

Naratrax

N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethane-1-sulfonamide

NA

NA

PO- The recommended dose is 1 to 2.5mg/day as single dose; maximum allowed dose is 5mg/day.

For the acute treatment of migraine attacks with or without aura in adults.

Some of the commonly reported adverse events of Naratriptan are agitation, paced heart beats, vomiting, headache, loss of coordination, overactive reflexes, pain or tightness in jaw, hemiplegia, weakness, central cyanosis, hallucination, dizziness and drowsiness.

• Co-administration of Naratriptan with ergot-containing drugs may result in prolonged vasospastic reactions.
• This drug may interact with SNRIs (Serotonin Norepinephrine Reuptake Inhibitors) SSRIs and (selective serotonin reuptake inhibitors).
• Concomitant use of Naratriptan with other 5-HT1 agonists is contraindicated.

Contraindicated in patients with history of heart disease, brain disorders, liver impairment and elderly.

Store at 20-25°C.

Molecular weight

335.464

Molecular formula

C17H25N3O2S

CAS number

121679-13-8

Precautions

An adjusted dose may be needed if the patient is on anti-depressant drug therapy.